Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Shares Outstanding (Diluted Average) (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Shares Outstanding (Diluted Average) data on record, last reported at $41.4 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 6.07% year-over-year to $41.4 million; the TTM value through Dec 2025 reached $41.4 million, up 6.07%, while the annual FY2025 figure was $41.4 million, 6.07% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $41.4 million in Q4 2025 per TRDA's latest filing, roughly flat from $41.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $41.4 million in Q4 2025 and bottomed at $31.2 million in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 4 years is $35.8 million, with a median of $34.5 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 18.49% in 2024, then increased 1.63% in 2025.
  • A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $31.3 million in 2022, then rose by 5.61% to $33.1 million in 2023, then grew by 18.01% to $39.0 million in 2024, then rose by 6.07% to $41.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $41.4 million in Q4 2025, $41.3 million in Q3 2025, and $41.2 million in Q2 2025.